Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003843 · ClinicalTrials.gov registry record
Irinotecan in Treating Patients With Colorectal Cancer
A clinical trial, sponsored by California Cancer Consortium.
- Terminated
- Registry status
- 28
- Enrollment target
NCT00003843: Clinical Trial study, sponsored by California Cancer Consortium.
NCT00003843 is a clinical trial that was terminated before completion, run by California Cancer Consortium. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003843 was terminated before completion, sponsored by California Cancer Consortium.
- TERMINATED
- Registry status
- 28 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have colorectal cancer.
Interventions
- GENETIC mutation analysis
- GENETIC polymorphism analysis
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 1998-10 |
| Est. Completion | 2001-02 |
Why NCT00003843 stopped before completion
NCT00003843 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which mutation analysis is the first listed.
NCT00003843 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003843 about?
NCT00003843 is a clinical study titled "Irinotecan in Treating Patients With Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have colorectal cancer.
What is the current status of trial NCT00003843?
This trial is currently terminated. The enrollment target is 28 participants. The study started on 1998-10. Estimated completion is 2001-02.
What interventions are being tested in trial NCT00003843?
The interventions under investigation include: mutation analysis (GENETIC), polymorphism analysis (GENETIC), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003843?
This trial is sponsored by California Cancer Consortium, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia